Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Eye tracking dysfunction and schizophrenia: a critical perspective

D L Levy1, P S Holzman, S Matthysse

  • 1McLean Hospital, Belmont, MA 02178.

Schizophrenia Bulletin
|January 1, 1993
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Functional disconnection between the visual cortex and right fusiform face area in schizophrenia.

Schizophrenia research·2019
Same author

Schizophrenia in adolescence.

Journal of youth and adolescence·2014
Same author

A clinical model for treatment of dyslexia.

Annals of dyslexia·2013
Same author

Express saccades and smooth pursuit eye movement function in schizophrenic, affective disorder, and normal subjects.

Journal of cognitive neuroscience·2013
Same author

The power and robustness of maximum LOD score statistics.

Annals of human genetics·2008
Same author

Processing of global, but not local, motion direction is deficient in schizophrenia.

Schizophrenia research·2003
Same journal

Reconsidering the Term "Treatment Resistant Schizophrenia".

Schizophrenia bulletin·2026
Same journal

The Effect of Semaglutide on Antipsychotic-Induced Weight Gain and Other Metabolic Parameters, among a Cohort of Inpatients.

Schizophrenia bulletin·2026
Same journal

Comparing Apples to Oranges Obscures Tortoises Beating Hares: The Relationship Between Rate of Antipsychotic Tapering and Relapse.

Schizophrenia bulletin·2026
Same journal

Beyond the Need for Speed: D2 Receptor Affinity Predicts Relapse after Antipsychotic Tapering in First Episode Psychosis.

Schizophrenia bulletin·2026
Same journal

Correction to: The Mini-CAARMS: Development and Validation of a Short Version of the Comprehensive Assessment of AT Risk Mental States to Facilitate Preventive Psychiatry.

Schizophrenia bulletin·2026
Same journal

Longitudinal Impact of Birthweight and its Polygenic Risk Score on Glucose and Antipsychotic-Induced Weight Gain in First Episode Psychosis.

Schizophrenia bulletin·2026
See all related articles

Eye tracking dysfunction (ETD) is common in schizophrenia patients and relatives, suggesting its potential as a biomarker in genetic studies. This review examines ETD

Area of Science:

  • Neuroscience
  • Psychiatry
  • Genetics

Background:

  • Eye tracking dysfunction (ETD) is frequently observed in schizophrenia patients and their first-degree relatives.
  • Replicated findings support ETD as a potential endophenotype for schizophrenia in genetic research.

Purpose of the Study:

  • Critically review the existing literature on eye tracking dysfunction (ETD) in schizophrenia.
  • Evaluate measurement issues, syndrome specificity, and statistical considerations for ETD research.
  • Examine the association of ETD with schizotypy and its stability over time.

Main Methods:

  • Literature review of studies on eye tracking dysfunction in schizophrenia.
  • Analysis of measurement techniques and quantitative indices for ETD.
  • Examination of familial specificity and association with schizotypy.

Related Experiment Videos

Main Results:

  • ETD is a robust finding in schizophrenia and relatives, supporting its use in genetic studies.
  • Specific measurement and analytical approaches are crucial for reliable ETD assessment.
  • ETD shows associations with schizotypy, but trait stability and medication effects require further investigation.

Conclusions:

  • Eye tracking dysfunction is a promising, heritable biomarker for schizophrenia research.
  • Further research is needed to refine ETD measurement and understand its clinical implications and stability.